Angioplasty or stenting for deep venous thrombosis
129 results
1 - 100
Angioplasty or stenting for deep venous thrombosis- Antiplatelet agents for the treatment of deep venous thrombosis
- Physical methods for preventing deep vein thrombosis in stroke
- Pharmacomechanical thrombectomy for iliofemoral deep vein thrombosis
- Combined oral contraceptives: venous thrombosis
- Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy
- Surgery for deep venous insufficiency
- Pharmacological interventions for preventing venous thromboembolism in people undergoing bariatric surgery
- Treatment of distal deep vein thrombosis
- Thrombophilia testing for prevention of recurrent venous thromboembolism
- Anticoagulant therapy for deep vein thrombosis (DVT) in pregnancy: Cochrane systematic review
- Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous thromboembolism following total hip or knee replacement
- Interventions for preventing venous thromboembolism following abdominal aortic surgery
- Pentasaccharides for the treatment of deep vein thrombosis
- Statins for primary prevention of venous thromboembolism: Cochrane systematic review
- Anaesthesia for hip fracture surgery in adults
- Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis
- Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of pulmonary embolism
- Graduated compression stockings for prevention of deep vein thrombosis
- Home versus in‐patient treatment for deep vein thrombosis
- Heparins and mechanical methods for thromboprophylaxis in colorectal surgery
- Effect of testing for cancer on cancer‐ or venous thromboembolism (VTE)‐related mortality and morbidity in people with unprovoked VTE
- CHIVA method for the treatment of chronic venous insufficiency
- Anticoagulants versus non‐steroidal anti‐inflammatories or placebo for treatment of venous thromboembolism
- Neuromuscular electrical stimulation for the prevention of venous thromboembolism
- Different types of intermittent pneumatic compression devices for preventing venous thromboembolism in patients after total hip replacement
- Low molecular weight heparin for prevention of venous thromboembolism in patients with lower‐limb immobilization
- Vena caval filters for the prevention of pulmonary embolism
- Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism
- Standard‐ versus extended‐duration anticoagulation for primary venous thromboembolism prophylaxis in acutely ill medical patients
- Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery
- Continuous passive motion for preventing venous thromboembolism after total knee arthroplasty: Cochrane systematic review
- Warfarin initiation nomograms for venous thromboembolism: Cochrane systematic review
- Anticoagulation for perioperative thromboprophylaxis in people with cancer
- Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
- Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism
- Venous thromboembolism prophylaxis for women at risk during pregnancy and the early postnatal period
- Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism
- Heparin, low molecular weight heparin and physical methods for preventing deep vein thrombosis and pulmonary embolism following surgery for hip fractures
- Low‐molecular‐weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke
- Pentasaccharides for the prevention of venous thromboembolism: Cochrane systematic review
- Methods for administering subcutaneous heparin during pregnancy
- Thrombolytic strategies versus standard anticoagulation for acute deep vein thrombosis of the lower limb
- Anticoagulants for people hospitalised with COVID‐19
- Tranexamic acid for reducing mortality in emergency and urgent surgery
- Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer
- Heparin for the prevention of venous thromboembolism in acutely ill medical patients (excluding stroke and myocardial infarction): Cochrane systematic review
- Unfractionated heparin versus low molecular weight heparins for avoiding heparin‐induced thrombocytopenia in postoperative patients
- Rutosides for prevention of post-thrombotic syndrome: Cochrane systematic review
- Thromboprophylaxis for trauma patients
- Self‐monitoring and self‐management of oral anticoagulation
- Statins for the primary prevention of venous thromboembolism
- Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair
- Prophylactic anticoagulants for non‐hospitalised people with COVID‐19
- Subacromial decompression surgery for rotator cuff disease
- Primary prophylaxis for venous thromboembolism in people undergoing major amputation of the lower extremity
- Haemodilution for acute ischaemic stroke
- Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism
- Interventions for lowering plasma homocysteine levels in dialysis patients
- Interventions for varicose veins and leg oedema in pregnancy
- Compression therapy for treating post‐thrombotic syndrome
- Rutosides for treatment of post-thrombotic syndrome: Cochrane systematic review
- Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid antibodies
- Interventions for implementation of thromboprophylaxis in hospitalized patients at risk for venous thromboembolism